188 related articles for article (PubMed ID: 25185738)
21. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
22. Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett's Esophagus.
Shah SL; Dunbar K
Curr Gastroenterol Rep; 2023 Dec; 25(12):374-379. PubMed ID: 37940812
[TBL] [Abstract][Full Text] [Related]
23. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
24. Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing.
Kuipers EJ
Gut; 2010 Feb; 59(2):148-9. PubMed ID: 20176635
[No Abstract] [Full Text] [Related]
25. Management of Barrett's oesophagus.
Sharma N; Ho KY
Br J Hosp Med (Lond); 2016 Jan; 77(1):33-7. PubMed ID: 26903454
[TBL] [Abstract][Full Text] [Related]
26. Barrett's oesophagus: frequency and prediction of dysplasia and cancer.
Falk GW
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):125-38. PubMed ID: 25743461
[TBL] [Abstract][Full Text] [Related]
27. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.
Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB
Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456
[TBL] [Abstract][Full Text] [Related]
28. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Steyerberg EW; Biermann K; Valkhoff VE; Kuipers EJ; Bruno MJ;
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):382-8. PubMed ID: 23200977
[TBL] [Abstract][Full Text] [Related]
30. Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer?
Mardini HE
Am J Gastroenterol; 2005 Apr; 100(4):978-9. PubMed ID: 15784046
[No Abstract] [Full Text] [Related]
31. Chemoprevention in Barrett's oesophagus.
Baruah A; Buttar NS
Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):151-65. PubMed ID: 25743463
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention in Barrett's oesophagus.
Gordon V; Jankowski J
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):569-79. PubMed ID: 22122772
[TBL] [Abstract][Full Text] [Related]
33. Medical treatment of Barrett's esophagus: can it prevent cancer?
Sampliner RE
Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
[TBL] [Abstract][Full Text] [Related]
34. Ask the doctor. Do PPI drugs for stomach acid reduce the risk of cancer in people (like me) with Barrett's esophagus?
Komaroff AL
Harv Health Lett; 2014 Apr; 39(6):2. PubMed ID: 24873004
[No Abstract] [Full Text] [Related]
35. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
36. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease.
Greene CL; Worrell SG; DeMeester TR
Ann Surg; 2015 Dec; 262(6):910-24. PubMed ID: 25822684
[TBL] [Abstract][Full Text] [Related]
37. GERD and Barrett's esophagus: diagnostic and management strategies in the geriatric population.
Morganstern B; Anandasabapathy S
Geriatrics; 2009 Jul; 64(7):9-12. PubMed ID: 19586085
[TBL] [Abstract][Full Text] [Related]
38. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
Yao H; Wang L; Li H; Xu S; Bai Z; Wu Y; Chen H; Goyal H; Qi X
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):79-88. PubMed ID: 34806503
[TBL] [Abstract][Full Text] [Related]
39. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation.
Morris CD; Byrne JP; Armstrong GR; Attwood SE
Br J Surg; 2001 Oct; 88(10):1357-62. PubMed ID: 11578292
[TBL] [Abstract][Full Text] [Related]
40. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
